285 related articles for article (PubMed ID: 21241452)
1. Accelerated hematopoietic stem cell aging in a mouse model of dyskeratosis congenita responds to antioxidant treatment.
Gu BW; Fan JM; Bessler M; Mason PJ
Aging Cell; 2011 Apr; 10(2):338-48. PubMed ID: 21241452
[TBL] [Abstract][Full Text] [Related]
2. Telomere dynamics and hematopoietic differentiation of human DKC1-mutant induced pluripotent stem cells.
Donaires FS; Alves-Paiva RM; Gutierrez-Rodrigues F; da Silva FB; Tellechea MF; Moreira LF; Santana BA; Traina F; Dunbar CE; Winkler T; Calado RT
Stem Cell Res; 2019 Oct; 40():101540. PubMed ID: 31479877
[TBL] [Abstract][Full Text] [Related]
3. Impaired Telomere Maintenance and Decreased Canonical WNT Signaling but Normal Ribosome Biogenesis in Induced Pluripotent Stem Cells from X-Linked Dyskeratosis Congenita Patients.
Gu BW; Apicella M; Mills J; Fan JM; Reeves DA; French D; Podsakoff GM; Bessler M; Mason PJ
PLoS One; 2015; 10(5):e0127414. PubMed ID: 25992652
[TBL] [Abstract][Full Text] [Related]
4. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells.
Batista LF; Pech MF; Zhong FL; Nguyen HN; Xie KT; Zaug AJ; Crary SM; Choi J; Sebastiano V; Cherry A; Giri N; Wernig M; Alter BP; Cech TR; Savage SA; Reijo Pera RA; Artandi SE
Nature; 2011 May; 474(7351):399-402. PubMed ID: 21602826
[TBL] [Abstract][Full Text] [Related]
5. Generation of dyskeratosis congenita-like hematopoietic stem cells through the stable inhibition of DKC1.
Carrascoso-Rubio C; Zittersteijn HA; Pintado-Berninches L; Fernández-Varas B; Lozano ML; Manguan-Garcia C; Sastre L; Bueren JA; Perona R; Guenechea G
Stem Cell Res Ther; 2021 Jan; 12(1):92. PubMed ID: 33514435
[TBL] [Abstract][Full Text] [Related]
6. Severity of X-linked dyskeratosis congenita (DKCX) cellular defects is not directly related to dyskerin (DKC1) activity in ribosomal RNA biogenesis or mRNA translation.
Thumati NR; Zeng XL; Au HH; Jang CJ; Jan E; Wong JM
Hum Mutat; 2013 Dec; 34(12):1698-707. PubMed ID: 24115260
[TBL] [Abstract][Full Text] [Related]
7. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita.
Parry EM; Alder JK; Lee SS; Phillips JA; Loyd JE; Duggal P; Armanios M
J Med Genet; 2011 May; 48(5):327-33. PubMed ID: 21415081
[TBL] [Abstract][Full Text] [Related]
8. p53 pathway activation by telomere attrition in X-DC primary fibroblasts occurs in the absence of ribosome biogenesis failure and as a consequence of DNA damage.
Carrillo J; González A; Manguán-García C; Pintado-Berninches L; Perona R
Clin Transl Oncol; 2014 Jun; 16(6):529-38. PubMed ID: 24065372
[TBL] [Abstract][Full Text] [Related]
9. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice.
Gu BW; Bessler M; Mason PJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10173-8. PubMed ID: 18626023
[TBL] [Abstract][Full Text] [Related]
10. The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita.
Zeng XL; Thumati NR; Fleisig HB; Hukezalie KR; Savage SA; Giri N; Alter BP; Wong JM
Hum Mol Genet; 2012 Feb; 21(4):721-9. PubMed ID: 22058290
[TBL] [Abstract][Full Text] [Related]
11. Dyskerin, telomerase and the DNA damage response.
Gu B; Bessler M; Mason PJ
Cell Cycle; 2009 Jan; 8(1):6-10. PubMed ID: 19106610
[TBL] [Abstract][Full Text] [Related]
12. Dyskeratosis congenita: a disorder of defective telomere maintenance?
Walne AJ; Marrone A; Dokal I
Int J Hematol; 2005 Oct; 82(3):184-9. PubMed ID: 16207588
[TBL] [Abstract][Full Text] [Related]
13. Acute telomerase components depletion triggers oxidative stress as an early event previous to telomeric shortening.
Ibáñez-Cabellos JS; Pérez-Machado G; Seco-Cervera M; Berenguer-Pascual E; García-Giménez JL; Pallardó FV
Redox Biol; 2018 Apr; 14():398-408. PubMed ID: 29055871
[TBL] [Abstract][Full Text] [Related]
14. Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita.
Fok WC; Shukla S; Vessoni AT; Brenner KA; Parker R; Sturgeon CM; Batista LFZ
Blood; 2019 Mar; 133(12):1308-1312. PubMed ID: 30728146
[TBL] [Abstract][Full Text] [Related]
15. Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer.
Marrone A; Dokal I
Expert Rev Mol Med; 2004 Dec; 6(26):1-23. PubMed ID: 15613268
[TBL] [Abstract][Full Text] [Related]
16. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita.
Wong JM; Collins K
Genes Dev; 2006 Oct; 20(20):2848-58. PubMed ID: 17015423
[TBL] [Abstract][Full Text] [Related]
17. Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita.
Vieri M; Kirschner M; Tometten M; Abels A; Rolles B; Isfort S; Panse J; Brümmendorf TH; Beier F
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003434
[TBL] [Abstract][Full Text] [Related]
18. Dyskeratosis congenita mutations in dyskerin SUMOylation consensus sites lead to impaired telomerase RNA accumulation and telomere defects.
Brault ME; Lauzon C; Autexier C
Hum Mol Genet; 2013 Sep; 22(17):3498-507. PubMed ID: 23660516
[TBL] [Abstract][Full Text] [Related]
19. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.
Shukla S; Jeong HC; Sturgeon CM; Parker R; Batista LFZ
Blood Adv; 2020 Jun; 4(12):2717-2722. PubMed ID: 32559291
[TBL] [Abstract][Full Text] [Related]
20. Dyskeratosis congenita, stem cells and telomeres.
Kirwan M; Dokal I
Biochim Biophys Acta; 2009 Apr; 1792(4):371-9. PubMed ID: 19419704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
